Liu M A, Kranz D M, Kurnick J T, Boyle L A, Levy R, Eisen H N
Proc Natl Acad Sci U S A. 1985 Dec;82(24):8648-52. doi: 10.1073/pnas.82.24.8648.
Antibodies to the clonally unique variable-region determinants (idiotype) of the antigen-specific alpha beta heterodimeric receptor of a clone of cytotoxic T cells (CTLs) were shown previously to render diverse cells, regardless of their own surface antigens, susceptible to lysis by that clone of CTLs. To extend these findings, we have sought to develop a general means for targeting cells for destruction by any CTL, without regard to its alpha beta idiotype and specificity for antigen. We explored the use of heteroantibody duplexes formed by joining covalently an antibody to the T3 complex (anti-T3), which is associated with the alpha beta receptors on all human mature T cells, and a second antibody, specific for an antigen on the intended target cell. The second antibody selected in this study was specific for the idiotype (Id) of the surface immunoglobulin of a human B-lymphoma (anti-Ig Id). In the presence of the anti-T3/anti-Ig Id heteroantibody duplex the B-lymphoma cells were lysed by a clone of human T8+ CTLs (of unrelated specificity) but not by a noncytotoxic clone of human T4+ helper T cells, and lysis by the CTLs was specifically blocked by the uncoupled anti-T3 or the uncoupled anti-Ig Id antibodies. The extent of the heteroantibody-dependent cytolysis depended both on the heteroantibody concentration and on whether the intended target cells or the CTL effectors were initially preincubated with the heteroantibody. Under optimal conditions, heteroantibody-dependent lysis of the surrogate target (B-lymphoma) cells by the CTLs compared favorably with lysis of their natural target cells by the same CTLs. Overall, our findings suggest that heteroantibody duplexes containing anti-T3 antibody may be capable of targeting selected cells, such as tumor cells, for destruction in vivo by the body's CTLs.
先前已表明,针对细胞毒性T细胞(CTL)克隆的抗原特异性αβ异二聚体受体的克隆独特可变区决定簇(独特型)的抗体,可使各种细胞,无论其自身表面抗原如何,都易于被该CTL克隆裂解。为了扩展这些发现,我们试图开发一种通用方法,用于使任何CTL靶向破坏细胞,而不考虑其αβ独特型和对抗原的特异性。我们探索了使用异源抗体双链体,其通过将与所有人类成熟T细胞上的αβ受体相关的抗T3复合物的抗体与针对预期靶细胞上抗原的第二种抗体共价连接而形成。本研究中选择的第二种抗体对人B淋巴瘤表面免疫球蛋白的独特型(Id)具有特异性(抗Ig Id)。在抗T3/抗Ig Id异源抗体双链体存在的情况下,B淋巴瘤细胞被人T8 + CTL克隆(无关特异性)裂解,但未被人T4 +辅助性T细胞的非细胞毒性克隆裂解,并且CTL的裂解被未偶联的抗T3或未偶联的抗Ig Id抗体特异性阻断。异源抗体依赖性细胞溶解的程度既取决于异源抗体的浓度,也取决于预期靶细胞或CTL效应细胞是否最初与异源抗体预孵育。在最佳条件下,CTL对替代靶标(B淋巴瘤)细胞的异源抗体依赖性裂解与相同CTL对其天然靶细胞的裂解相比具有优势。总体而言,我们的发现表明,含有抗T3抗体的异源抗体双链体可能能够使选定的细胞,如肿瘤细胞,在体内被机体的CTL破坏。